However, several clinical trials have found residual CML LSCs in most patients who maintain TFR, even when BCR::ABL is monitored using a highly sensitive assay, such as ddPCR.53, 54. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.